Association of short tandem repeat polymorphism in the promoter of prostate cancer antigen 3 gene with the risk of prostate cancer

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Zhou, Wu ^a   Chen, Zhanguo ^a   Hu, Wangqiang ^a   Shen, Mo ^a   Zhang, Xiaoxia ^b   Li, Chengdi ^a   Wen, Zhiliang ^a   Wu, Xiuling ^a   Hu, Yuanping ^a   Zhang, Xiaohua ^a   Duan, Xiuzhi ^a   Han, Xiucui ^a   Tao, Zhihua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b Ningbo Municipal Hospital of Traditional Chinese Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RISK; CHI SQUARE TEST; CHINESE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER ANTIGEN 3; RISK ASSESSMENT; RISK FACTOR; SHORT TANDEM REPEAT; TRANSCRIPTION REGULATION; TUMOR GENE; AGED; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROSTATE TUMOR;

MICROSATELLITE DNA; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS;

EID: 79957812413     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020378     Document Type: Article

References (15)

1. Landis SH, Murray T, Bolden S, Wingo PA, (1999) Cancer statistics, 1999. CA Cancer J Clin 49: 8-31,31.
2. Paulson DF, Moul JW, Walther PJ, (1990) Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 144: 1180-1184.
3. Walsh PC, Partin AW, Epstein JI, (1994) Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152: 1831-1836.
4. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, et al. (1994) Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152: 1850-1857.
5. Pound CR, Partin AW, Epstein JI, Walsh PC, (1997) Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 24: 395-406.
6. Epstein JI, Carmichael MJ, Pizov G, Walsh PC, (1993) Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol 150: 135-141.
7. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE, (1993) An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA 269: 2633-2636.
8. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350: 2239-2246.
9. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, et al. (1999) DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59: 5975-5979.
10. Verhaegh GW, van Bokhoven A, Smit F, Schalken JA, Bussemakers MJ, (2000) Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. J Biol Chem 275: 37496-37503.
11. Tao Z, Shen M, Zheng Y, Mao X, Chen Z, et al. (2010) PCA3 gene expression in prostate cancer tissue in a Chinese population: quantification by real-time FQ-RT-PCR based on exon 3 of PCA3. Exp Mol Pathol 89: 58-62.
12. Chen FP, Chen LL, Shen M, Chen W, Tao ZH, et al. (2008) [Detection of urine DD3/PSA mRNA ratio by duplex TaqMan RT-PCR assay and evolution of its primary application]. Zhonghua Yi Xue Za Zhi 88: 261-264.
13. Floriano-Sanchez E, Cardenas-Rodriguez N, Castro-Marin M, Alvarez-Grave P, Lara-Padilla E, (2009) DD3(PCA3) gene expression in cancer and prostatic hyperplasia. Clin Invest Med 32: E258.
14. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, et al. (2002) DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62: 2695-2698.
15. Klecka J, Holubec L, Pesta M, Topolcan O, Hora M, et al. (2010) Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis. Anticancer Res 30: 665-670.